Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression
- 10 November 2011
- journal article
- research article
- Published by Taylor & Francis in Journal of Neurogenetics
- Vol. 25 (4) , 152-166
Abstract
There is growing evidence suggesting that antagonists of group II metabotropic glutamate receptors (mGluR2/3) exhibit antidepressant-like properties in several preclinical models of depression. However, all those studies have been performed using competitive group II non-selective orthosteric antagonists. In this study we extensively characterized a group II selective negative allosteric modulator (4-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-7-methyl-8-trifluoromethyl-1,3-dihydrobenzo[b][1,4]diazepin-2-one, namely RO4491533, Woltering et al., 2010) in several in vitro biochemical assays and in vivo models of depression. In vitro, RO4491533 completely blocked the glutamate-induced Ca2 + mobilization and the glutamate-induced accumulation in [35S]GTPγS binding in cells expressing recombinant human or rat mGluR2 and in native tissues. Results from Schild plot experiments and reversibility test at the target on both cellular and membrane-based assays confirmed the negative allosteric modulator properties of the compound. RO4491533 was equipotent on mGluR2 and mGluR3 receptors but not active on any other mGluRs. RO4491533 has acceptable PK properties in mice and rats, is bioavailable following oral gavage (F = 30%) and brain-penetrant (CSF conc/total plasma conc ratio = 0.8%). RO4491533 appeared to engage the central mGluR2 and mGluR3 receptors since the compound reversed the hypolocomotor effect of an mGluR2/3 orthosteric agonist LY379268 in a target-specific manner, as did the group II orthosteric mGluR2/3 antagonist LY341495. RO4491533 and LY341495 dose-dependently reduced immobility time of C57Bl6/J mice in the forced swim test. Also, RO4491533 and LY341495 were active in the tail suspension test in a line of Helpless (H) mice, a putative genetic model of depression. These data suggest that mGluR2/3 receptors are viable targets for development of novel pharmacotherapies for depression.Keywords
This publication has 56 references indexed in Scilit:
- Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer’s Disease: Selective Activation of mGlu2 Receptors Amplifies β-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is NeuroprotectiveMolecular Pharmacology, 2011
- Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal NeuronsPLOS ONE, 2009
- Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disordersNature Reviews Drug Discovery, 2009
- Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depressionEuropean Journal of Pharmacology, 2008
- Allosteric modulation of the muscarinic M4receptor as an approach to treating schizophreniaProceedings of the National Academy of Sciences, 2008
- Molecular Signalling Mediating the Protective Effect of A1 Adenosine and mGlu3 Metabotropic Glutamate Receptor Activation against Apoptosis by Oxygen/Glucose Deprivation in Cultured AstrocytesMolecular Pharmacology, 2007
- MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activityNeuropharmacology, 2004
- Altered Transcript Expression of NMDA Receptor-Associated Postsynaptic Proteins in the Thalamus of Subjects With SchizophreniaAmerican Journal of Psychiatry, 2003
- G Protein-Coupled Receptor Allosterism and ComplexingPharmacological Reviews, 2002
- Regulation of Neurotransmitter Release by Metabotropic Glutamate ReceptorsJournal of Neurochemistry, 2000